Skip to Content

Pelzont

Active Substance: laropiprant / nicotinic acid
Common Name: laropiprant / nicotinic acid
ATC Code: C10AD52
Marketing Authorisation Holder: Merck Sharp & Dohme Ltd
Active Substance: laropiprant / nicotinic acid
Status: Withdrawn
Authorisation Date: 2008-07-03
Therapeutic Area: Dyslipidemias
Pharmacotherapeutic Group: Lipid-modifying agents

Therapeutic Indication

Pelzont is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (LDL) cholesterol and triglycerides and low high-density-lipoprotein (HDL)cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).

Pelzont should be used in patients in combination with 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA)-reductase inhibitors (statins), when the cholesterol lowering effect of HMG-CoA-reductase inhibitor monotherapy is inadequate. It can be used as monotherapy only in patients in whom HMG-CoA-reductase inhibitors are considered inappropriate or not tolerated. Diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with Pelzont.

The marketing authorisation for Pelzont has been withdrawn at the request of the marketing-authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide